
Valion Bio pivots to integrated platform model with manufacturing push
Valion Bio is transitioning from a single-asset developer into an integrated biotechnology platform, leveraging a 200-fold manufacturing scale-up at its Velocity Bioworks subsidiary to anchor its biodefense pipeline and planned expansion into oncology supportive care, according to an update from the company on July 14, 2026.

























